Tonix Pharmaceuticals has completed the acquisition of two currently-marketed products from Upsher-Smith Laboratories: Zembrace SymTouch 3 mg and Tosymra 10 mg. Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults. As previously announced, these products collectively generated product sales of approximately $23M for the full year 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
- Biotech Alert: Searches spiking for these stocks today
- Tonix to acquire Zembrace SymTouch, Tosymra from Upsher-Smith
- Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
- Tonix Pharmaceuticals announces publication of Phase 3 RELIEF trial results